Published in Cancer Res on November 01, 2008
Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene (2010) 1.62
Promiscuous partnerships in Ewing's sarcoma. Cancer Genet (2011) 1.41
Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family. Sarcoma (2010) 1.11
Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res (2011) 1.09
EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo. Cancer Res (2010) 1.08
Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol (2010) 1.06
EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res (2012) 1.04
Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome Med (2010) 1.01
Animal models of soft-tissue sarcoma. Dis Model Mech (2010) 1.01
Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma (2010) 0.99
Mesenchymal stem cell transformation and sarcoma genesis. Clin Sarcoma Res (2013) 0.95
ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. Genes Cancer (2013) 0.91
The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J Cell Biochem (2010) 0.91
A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Dis Model Mech (2011) 0.90
Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res (2012) 0.89
TEThered to Runx: novel binding partners for runx factors. Blood Cells Mol Dis (2010) 0.86
Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Epigenetics (2014) 0.86
Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res (2014) 0.83
Primary neoplasms of bones in mice: retrospective study and review of literature. Vet Pathol (2011) 0.83
The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse. Oncogene (2014) 0.82
Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma (2010) 0.82
Salient features of mesenchymal stem cells-implications for Ewing sarcoma modeling. Front Oncol (2013) 0.82
The first European interdisciplinary ewing sarcoma research summit. Front Oncol (2012) 0.82
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget (2016) 0.81
Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery. Expert Opin Drug Discov (2013) 0.78
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget (2016) 0.78
Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma (2011) 0.78
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease. ISRN Oncol (2012) 0.77
Loss of Ewing sarcoma EWS allele promotes tumorigenesis by inducing chromosomal instability in zebrafish. Sci Rep (2016) 0.77
Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget (2016) 0.77
The cell cycle regulator CCDC6 is a key target of RNA-binding protein EWS. PLoS One (2015) 0.76
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma. Genes Cancer (2015) 0.76
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein. Oncotarget (2016) 0.76
An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development. Stem Cell Reports (2016) 0.76
Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. Mol Ther Nucleic Acids (2017) 0.75
Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell Death Dis (2016) 0.75
The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute. Stem Cell Investig (2014) 0.75
Widespread Chromatin Accessibility at Repetitive Elements Links Stem Cells with Human Cancer. Cell Rep (2016) 0.75
A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res (1995) 12.21
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med (2003) 8.48
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis (2002) 6.11
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev (2000) 5.71
Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol (2004) 5.37
Zp3-cre, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. Curr Biol (1997) 4.46
Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res (2005) 3.33
The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol (1993) 2.84
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res (2007) 2.74
The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell (2002) 2.28
DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol (1994) 2.18
EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol (2007) 1.72
Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol (1987) 1.68
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol (2005) 1.66
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet (1999) 1.57
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene (2001) 1.53
A rapid and non-invasive selection of transgenic embryos before implantation using green fluorescent protein (GFP). FEBS Lett (1995) 1.48
Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol (1995) 1.47
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res (2005) 1.46
Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene (2001) 1.35
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem (2003) 1.34
EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet (1997) 1.27
Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene (2003) 1.27
Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res (2003) 1.25
Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol (2002) 1.13
The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res (2004) 1.06
The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells. PLoS Biol (2005) 1.01
EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene (1996) 1.00
Ewing's sarcoma: new approaches to histogenesis and molecular plasticity. Lab Invest (1992) 0.97
Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant (2001) 0.97
Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol (2003) 0.94
Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol (2002) 0.89
Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. Hum Pathol (1999) 0.79
The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev Dyn (2007) 8.86
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem (2002) 2.68
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med (2007) 2.03
Prospective head-movement correction for high-resolution MRI using an in-bore optical tracking system. Magn Reson Med (2009) 2.02
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med (2012) 1.93
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol (2003) 1.93
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol (2002) 1.93
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol (2005) 1.79
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol (2006) 1.79
Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 1.78
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet (2003) 1.68
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest (2007) 1.64
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 1.63
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol (2007) 1.59
Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol (2007) 1.58
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One (2008) 1.55
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest (2011) 1.54
Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med (2007) 1.51
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res (2006) 1.47
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer (2010) 1.42
p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A (2006) 1.41
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One (2009) 1.39
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res (2005) 1.39
RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis (2003) 1.37
Distinct roles of Mdm2 and Mdm4 in red cell production. Blood (2006) 1.36
Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol (2006) 1.35
C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol (2010) 1.34
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res (2003) 1.32
The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity (2010) 1.31
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
Multiple stress signals activate mutant p53 in vivo. Cancer Res (2011) 1.27
Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys (2009) 1.26
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol (2002) 1.24
Retracted Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem (2010) 1.24
From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets (2006) 1.23
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res (2010) 1.23
Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol (2007) 1.22
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest (2011) 1.21
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation (2007) 1.21
Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell (2010) 1.21
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol (2008) 1.19
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol (2007) 1.17
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood (2012) 1.16
A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol (2010) 1.16
Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol (2010) 1.15
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis (2009) 1.15
Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis (2002) 1.14
p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res (2010) 1.12
Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res (2009) 1.11
The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev (2013) 1.11
Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther (2010) 1.10
Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene (2002) 1.09
Poly-(3-hexylthiophene) self-assembled monolayer based cholesterol biosensor using surface plasmon resonance technique. Biosens Bioelectron (2006) 1.07
p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell (2005) 1.06
Li-Fraumeni syndrome: a p53 family affair. Cell Cycle (2005) 1.05
E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol (2009) 1.04